Skip to content

Investigation for chronic Idiopathic Urticaria

Autologous Serum Skin Test as a Diagnostic Aid in Chronic Idiopathic Urticaria

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013030912758N1
Enrollment
54
Registered
2013-03-25
Start date
2009-11-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urticaria. Idiopathic urticaria

Interventions

Intervention 1: The Autologous Serum Skin Test (ASST) was performed by drawing 2cubic centimeters of venous blood and stored in a plane tube(not heparinized) and allowed to clot at room temperature ,a
Diagnosis
The Autologous Serum Skin Test (ASST) was performed by drawing 2cubic centimeters of venous blood and stored in a plane tube(not heparinized) and allowed to clot at room temperature ,after that the se
At the same time a control test is done by injecting the same volume of normal saline at least 5 centimeters away from the serum injection site

Sponsors

Iraqi Board for Medical specializations
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: All patients with chronic idiopathic urticaria who have active urticaria at time of presentation and the current attack started at least six week before the test. Exclusion criteria: children younger than 15 years of age and pregnant women were excluded from the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Wheal and flare. Timepoint: 30 minutes after intradermal injection of 0.05 ml of the patient’s serum into patient’s forearm. Method of measurement: wheal and flare at the tested site of a diameter (measured by taking the mean of the largest two diameters) at least 1.5 millimeters more than the wheal and flare induced at the control site.

Secondary

MeasureTime frame
Wheal and flare. Timepoint: 45 minutes after intradermal injection of the patient’s serum into patient’s forearm. Method of measurement: wheal and flare at the tested site of a diameter (measured by taking the mean of the largest two diameters) at least 1.5 millimeters more than the wheal and flare induced at the control site.

Countries

Iraq

Contacts

Public ContactProfessor Hayder R. Al-Hamamy

Head of Department of Dermatology and Venereology, College of Medicine, University of Baghdad, Medic

Hayder317@gmail.com009647901309356

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026